Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Other Non-Current Assets (2016 - 2025)

Marimed (MRMD) has disclosed Other Non-Current Assets for 13 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed 0.0% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $1.5 million for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.5 million at Marimed, up from $1.1 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $13.0 million in Q1 2024, with the low at $97950.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $3.6 million, with a median of $1.1 million recorded in 2025.
  • The sharpest move saw Other Non-Current Assets soared 1229.59% in 2023, then plummeted 91.39% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $98000.0 in 2021, then skyrocketed by 944.9% to $1.0 million in 2022, then surged by 1124.32% to $12.5 million in 2023, then tumbled by 88.04% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.5 million, $1.1 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.